DNDI-6174
Progress the pre-clinical development of DNDI-6174 for the treatment of visceral leishmaniasis
current phase of drug development
updated 1 Jun 2021
Emerging from the leishmaniasis L205 lead optimization series after showing great efficacy in vivo in both mouse and hamster models for visceral leishmaniasis, DNDI-6174 was nominated as a pre-clinical candidate for visceral leishmaniasis in 2019. DNDI-6174 presents a new mode of action among compounds in DNDi’s leishmaniasis portfolio as well as a predicted low human dose and a very promising safety margin.
Project updates
2020
Further characterization of DNDI-6174 and preparations to initiate pre-clinical activities continued in 2020. With support from Japan’s Global Health Innovative Technology Fund (GHIT Fund), DNDi and Eisai will start collaborating in Q2 2021 to conduct pre-clinical development activities and prepare the way for future Phase I clinical studies in healthy human volunteers.
2019
Planning is underway to start pre-clinical activities in 2020.
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.
